Clinical Trials Logo
  1. Home
  2. HIV I Infection
  3. NCT04585737

Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF — DYAD  

HIV I Infection Clinical Trial

Official title:
Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine in Virologically-suppressed Adults Living With HIV on Bictegravir/Tenofovir Alafenamide/emtricitabine-the DYAD Study

Clinical Trial Summary

Phase 4, randomized, open-label study to evaluate the efficacy, safety and tolerability of switching virologically suppressed adults living with HIV on bictegravir/tenofovir alafenamide/emtricitabine to dolutegravir/lamivudine

Clinical Trial Description

Randomized, open-label, active-controlled study of virologically suppressed participants living with HIV Participants who provide written informed consent and meet all the eligibility criteria will be randomized in a 2:1 ratio to one of the following 2 treatment groups: Treatment Group 1 (n=148): FDC of DTG/3TC (50mg/300mg) administered orally, once daily (QD), without regard to food. Treatment Group 2 (n=74): Stay on baseline regimen consisting of FDC of B/F/TAF (50mg/200mg/ 25mg) (taken as prescribed) without regard to food. Randomization will be stratified by gender and race at entry given that this study aims to enroll at least 30% of participants who are female and African American. All participants will be responsible for using their insurance plan to obtain coverage for DTG/3TC and or B/F/TAF, in addition to any labs required by the study. This expectation is clearly outlined in the informed consent. The study team will work with participants to minimize their co-pays for study medications and labs through the use of manufacturer and other external assistance programs. Study duration will be 48 weeks. Number of participants planned: Approximately 222 participants Target Population: HIV-1 infected adult participants who are virologically suppressed (HIV-1 RNA<50 copies/mL) on FDC of B/F/TAF (50mg/200mg/ 25mg) ≥ 3 months prior to screening ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04585737
Study type Interventional
Source Orlando Immunology Center
Contact
Status Completed
Phase Phase 4
Start date September 22, 2020
Completion date August 10, 2023
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06282783 - Studying Topiramate for Re-Activating the HIV-1 Reservoir Phase 1/Phase 2
Not yet recruiting NCT03622177 - Role of the IL33/Amphiregulin Pathway as a Potential Therapeutic Target in HIV Infection
Recruiting NCT05854381 - To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV Phase 1
Enrolling by invitation NCT05071378 - Leveraging Family-Based Assets for Black MSM In House Ball Communities N/A
Completed NCT05421806 - A Cohort Study of Use of Doravirine (DOR) Based Regimens in Clinical Practice in Europe DoRavirine Europe Real World/
Completed NCT04568395 - Acute Effects of TCIG vs ECIG in PLWH N/A
Recruiting NCT04887675 - Neuroinflammation and Neurodegeneration in HIV-positive Subjects Switched and Initially Treated With INSTI N/A
Recruiting NCT04820933 - Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV Early Phase 1
Completed NCT03584048 - Charlotte Retention in Care Study
Recruiting NCT06005610 - Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy Phase 2
Recruiting NCT05947890 - Evaluating the Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living With and Without HIV in South Africa Phase 2
Recruiting NCT05187429 - Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy Phase 1/Phase 2
Active, not recruiting NCT05601128 - A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA Phase 3
Completed NCT04675255 - Assessing the Impact of INSTI to PI Switch on Insulin Sensitivity and Fat Metabolism N/A
Recruiting NCT05110963 - Intervention to Improve HIV Care Retention by Addressing Stigma Stigmatized Environments N/A
Completed NCT03986099 - Community Based Antiretroviral Therapy (CBART) Among Children on Chronic ART N/A
Completed NCT04971343 - Access HIV Ag/Ab Combo Assay - European Union (EU) Clinical Trial Protocol
Completed NCT04725877 - VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers Phase 1
Recruiting NCT04618198 - Early Empiric Anti-Mycobacterium Tuberculosis Therapy for Sepsis in Sub-Saharan Africa Phase 3
Completed NCT05383456 - The Visceral Adiposity Measurement and Observation Study